Innoviz Chief R&D Officer reports holdings
Innoviz Technologies Ltd. Chief R&D Officer Avishay Ben Moscovici filed an initial ownership report showing his equity position in the company.
Rhea-AI Filing Summary
Innoviz Technologies Ltd. Chief R&D Officer Avishay Ben Moscovici filed an initial ownership report showing his equity position in the company. He directly holds 330,665 ordinary shares, along with multiple share option grants over ordinary shares with exercise prices ranging from $0.5695 to $11.50 and expirations between 2027 and 2032.
The filing also notes 172,296 ordinary shares issuable upon vesting of restricted share units (RSUs), granted between 2022 and 2025, with quarterly vesting schedules running through 2029, subject to his continued service. Each RSU represents a contingent right to receive one ordinary share.
Positive
- None.
Negative
- None.
Insider Trade Summary
9 transactions reported
Mixed
9 txns
Insider
Moscovici Avishay Ben
Role
Chief R&D Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Share Option | -- | -- | -- |
| holding | Share Option | -- | -- | -- |
| holding | Share Option | -- | -- | -- |
| holding | Share Option | -- | -- | -- |
| holding | Share Option | -- | -- | -- |
| holding | Share Option | -- | -- | -- |
| holding | Share Option | -- | -- | -- |
| holding | Share Option | -- | -- | -- |
| holding | Ordinary Shares | -- | -- | -- |
Holdings After Transaction:
Share Option — 352,908 contracts (Direct);
Ordinary Shares — 330,665 shares (Direct)
Footnotes (7)
- F1. Includes 172,296 ordinary shares issuable upon vesting of restricted share units ("RSUs"); of which (a) 4,010 RSUs granted August 9, 2022, vesting in equal quarterly installments through 2026; (b) 12,810 RSUs granted August 1, 2023, vesting quarterly through 2027; (c) 14,636 RSUs granted February 27, 2024, with 2,684 vesting quarterly through 2027 and 11,952 vesting quarterly through 2028; (d) 28,280 RSUs granted August 20, 2024, vesting quarterly through 2028; (e) 14,928 RSUs granted February 25, 2025, vesting quarterly through 2029; (f) 49,584 RSUs granted August 5, 2025, one-fourth vesting on August 5, 2026, remainder vesting quarterly through 2029; and (g) 48,048 RSUs granted November 11, 2025, one-fourth vesting on November 11, 2026, remainder vesting quarterly through 2029. Vesting is subject to the Reporting Person remaining a service provider of the Issuer on each applicable vesting date. Each RSU represents a contingent right to receive one ordinary share.
- F2. No exercise price is applicable.
- F3. Immediately exercisable.
- F4. Share options granted on August 9, 2022. Includes 21,056 vested options, and 3,008 unvested options, which shall vest in equal quarterly installments through 2026, subject to the Reporting Person remaining a service provider of the Issuer on each applicable vesting date.
- F5. Share options granted on August 1, 2023. Includes 18,840 vested options, and 11,304 unvested options, which shall vest in equal quarterly installments through 2027, subject to the Reporting Person remaining a service provider of the Issuer on each applicable vesting date.
- F6. Share options granted on August 20, 2024. Includes 18,180 vested options, and 30,300 unvested options, which shall vest in equal quarterly installments through 2028, subject to the Reporting Person remaining a service provider of the Issuer on each applicable vesting date.
- F7. Share options granted on August 5, 2025. Includes no vested options, and 53,120 unvested options, with one-fourth of the options vesting on August 5, 2026, and the remaining shall vest in equal quarterly installments through 2029, subject to the Reporting Person remaining a service provider of the Issuer on each applicable vesting date.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does Innoviz Technologies (INVZ) Chief R&D Officer report on this Form 3?
The Chief R&D Officer reports his initial equity holdings in Innoviz, including 330,665 ordinary shares held directly and several share option grants over ordinary shares, plus a significant block of RSUs that may convert into shares over time.
What stock options are disclosed for the Innoviz (INVZ) Chief R&D Officer?
The filing lists multiple share option grants over ordinary shares with exercise prices from $0.5695 to $11.50 and expiration dates between 2027 and 2032, reflecting a mix of vested and unvested options tied to continued service.
How many RSUs are reported by the Innoviz (INVZ) officer and how do they vest?
The officer reports 172,296 ordinary shares issuable upon RSU vesting. These RSUs were granted from 2022 to 2025 and generally vest in equal quarterly installments through 2029, contingent on the officer remaining a service provider.
Does this Innoviz (INVZ) Form 3 show insider buying or selling activity?
The Form 3 does not show buying or selling activity. It is an initial ownership report that outlines existing holdings of ordinary shares, share options and RSUs, rather than recording new market transactions in Innoviz stock.
AI-generated analysis. How Rhea-AI works. Not financial advice.
